Prospective Evaluation Of Exercise-Induced Cardiac Conduction Instability In Predicting Ventricular Fibrillation Events In Hypertrophic Cardiomyopathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-10

Study Completion Date

2026-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hypertrophic Cardiomyopathy (HCM) is an inherited heart condition. Most people who have it are unaware of any problems relating to it. Unfortunately, a small number of people with the condition can suddenly develop a dangerous fast heart beat that can lead to death. There is no cure, but implanting a cardioverter-defibrillator (ICD), which is like a pacemaker can save the life of affected individuals. However, ICD implantation has its own problems, so choosing who gets an ICD is a very important decision.

The current approach for recommending people for an ICD has limitations and a better method is needed. Investigators have developed a new technique called the 'Ventricular Conduction Stability' (V-CoS). This involves wearing a special vest which records electrical signals from the heart, and then running on a treadmill. Investigators have used it to identify abnormalities in the hearts of people with HCM who have also survived a life-threatening event.

This project aims to test new tool against current methods to ascertain which is better at identifying patients who should have an ICD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

3D Non-invasive Myocardial Electrical Propagation Mapping as a New Tool to Predict Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy

NCT03550573

Hypertrophic Cardiomyopathy

COMPLETED NA

Pilot Study of Hypertrophic Cardiomyopathy & Implantable Cardioverter Defibrillator Assessment: (Subcutaneous vs Transvenous)

NCT05938283

Implantable Defibrillator User Hypertrophic Cardiomyopathy Implantable Cardioverter Ventricular Lead Dysfunction or Complication +1 more

RECRUITING NA

PREVENT-HF: Prevention of Heart Failure Events With Impedance Cardiography Testing

NCT00409916

Heart Failure, Congestive

UNKNOWN PHASE4

Optimisation of Decision Making for Defibrillator Implantation in Hypertrophic Cardiomyopathy

NCT03846297

Hypertrophic Cardiomyopathy

RECRUITING

Study of the Implantable Cardioverter Defibrillator (ICD) Intracardiac Electrograms

NCT00916435

Congestive Heart Failure Sudden Cardiac Death Arrhythmia +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To find out how accurate V-CoS test and other ECGI metrics are, the investigator will study patients with confirmed Hypertrophic Cardiomyopathy currently thought to be high risk. They will be tested by V-CoS and have their conventional risk score worked out. Patients will be followed up currently to 5 years to check if they have had a dangerously fast heartbeat or problems with their defibrillator.

Patients will be recruited primarily from three specialist Inherited Cardiac Diseases clinics in London, but will include other centres as well.

Participants will be interviewed in clinic by our team to explain the study, answer questions and to get permission for the test. Participants can leave the study at any time - it will not affect the way the investigator treat them as patients.

Participants will spend a half day at the Cardiac Investigations unit. This day will consist of, in this order:

1. Any remaining discussion of the study, the tests and the consent needed with the participant.
2. Putting the sensor vest on which will be done by one of the research staff. It looks like a waistcoat with electrical connections and is secured to the patient's skin with conductive jelly underneath to help the recordings.
3. A 3D 'CT' scan of the chest is done to show how the sensor vest lines up with the heart. The scan has a low radiation dose, equivalent to 6 months of natural background radiation.
4. Then the participant will run on the treadmill whilst the vest is used to take recordings. The lowest V-CoS test score will be recorded from each participant and used to predict their risk.
5. Participants will have the V-CoS test repeated whilst doing the Valsalva maneuver. This is when participant attempt to blow out as much air as possible from lungs, but without letting any out from mouth or nose.
6. Participants with implanted pacemakers or defibrillators may undergo a test where the investigator give them extra heartbeats using their implanted device. The sensor vest will be used to take recordings. The investigator want to see if V-CoS scores can be lowered further than with exercise testing.
7. Participants will have a blood test or cheek swab to send for genetic testing. Then participants will be followed up. If they have a defibrillator they will be telephoned and seen in the ICD clinic every 6 months. If they do not have a defibrillator they will get follow up by telephone every 3 months. Maximum follow up is 5 years.

The results will be looked at by independent researchers to reduce bias.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertrophic Cardiomyopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Prospective cohort study

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test arm

All patients. Single arm study

Group Type EXPERIMENTAL

Non-invasive ECG imaging - CardioInsight test

Intervention Type DIAGNOSTIC_TEST

1. Consent session
2. Fitting of ECGi vest and CT scan of the chest
3. Supervised exercise test and Valsalva maneuvre
4. Programmed stimulation via ICD (selected participants)
5. Blood tests - genetics

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non-invasive ECG imaging - CardioInsight test

1. Consent session
2. Fitting of ECGi vest and CT scan of the chest
3. Supervised exercise test and Valsalva maneuvre
4. Programmed stimulation via ICD (selected participants)
5. Blood tests - genetics

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Does the patient have maximum wall thickness \>13mm by any imaging technique? i) If so, does the patient have a first degree relative (sibling, parent, child) with a formal diagnosis of HCM -AND- ii) Does the patient have any of the following: Does the patient have any of the following: abnormal Doppler myocardial imaging or strain, incomplete systolic anterior motion, elongation of mitral valve leaflets and abnormal papillary muscles, abnormal ECG? -OR-
* Does the patient have maximum wall thickness 15mm or more by any imaging technique?
* Is the patient male or female 18-100years of age?
* High or intermediate risk for sudden cardiac death from HCM based on the ESC risk calculator predicting \>4% risk over 5 years by specialist inherited cardiac disease clinic. This would use the online SCD-risk calculator

Exclusion Criteria

* Patients with previous cardiac arrest
* Patients with haemodynamically unstable VT needing medical attention.
* Evidence of one of the following conditions causing secondary hypertrophy:

a. Hypertension \>200/100; Severe aortic stenosis; Anderson-Fabry disease; Myocarditis; Congenital heart disease; TTR-related amyloidosis; Myotonic dystrophy; Mitochondrial disease, Noonan syndrome, LEOPARD syndrome, Costello syndrome, Danon disease, Friedreich's ataxia, Glycogen storage disease, FHLI mutation, PRKAG2 mutations
* Patients with previous appropriate therapy from an ICD.
* Patients under the age of 18 years
* Patients who are not safe to discontinue Beta blockers
* Patients unable to exercise due to musculoskeletal problems
* Patients with skin allergies to ECG gel/electrodes.
* Life expectancy shorter than the duration of the trial.
* Pregnant or planning pregnancy at the time of CT scan.
* Patients unable to consent to the study protocol or provide contact details for follow up.
* Patients currently participating in an interventional medical or device trial.

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No